The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Can early detection of multiple myeloma improve patient outcomes?
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, Miami, FL, highlights the potential for early detection of multiple myeloma (MM) to improve patient outcomes. Screening and genomic studies indicate that all patients with MM have a preceding stage known as monoclonal gammopathy of undetermined significance (MGUS). The ongoing iStopMM trial in Iceland (NCT03327597) aims to determine if early monitoring of this phase can enhance patient outcomes. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex; Honoraria: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex; Membership on an entity’s Board of Directors or advisory committees: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex; Membership on independent data monitoring committees: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex.
